vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TRUSTMARK CORP (TRMK). Click either name above to swap in a different company.
TRUSTMARK CORP is the larger business by last-quarter revenue ($204.1M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 8.9%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Trustmark is an insurance company. According to Crain's Chicago Business magazine, Trustmark ranks #69 among Chicago's Largest Privately Held Companies in 2018.
ESPR vs TRMK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $204.1M |
| Net Profit | — | $57.9M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 34.7% |
| Net Margin | — | 28.4% |
| Revenue YoY | 143.7% | 4.5% |
| Net Profit YoY | — | 2.8% |
| EPS (diluted) | $0.32 | $0.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $204.1M | ||
| Q3 25 | $87.3M | $202.4M | ||
| Q2 25 | $82.4M | $198.6M | ||
| Q1 25 | $65.0M | $194.6M | ||
| Q4 24 | $69.1M | $155.8M | ||
| Q3 24 | $51.6M | $192.3M | ||
| Q2 24 | $73.8M | $141.0M | ||
| Q1 24 | $137.7M | $172.2M |
| Q4 25 | — | $57.9M | ||
| Q3 25 | $-31.3M | $56.8M | ||
| Q2 25 | $-12.7M | $55.8M | ||
| Q1 25 | $-40.5M | $53.6M | ||
| Q4 24 | — | $56.3M | ||
| Q3 24 | $-29.5M | $51.3M | ||
| Q2 24 | $-61.9M | $73.8M | ||
| Q1 24 | $61.0M | $41.5M |
| Q4 25 | 50.6% | 34.7% | ||
| Q3 25 | -11.4% | 34.5% | ||
| Q2 25 | 8.6% | 34.7% | ||
| Q1 25 | -34.0% | 33.6% | ||
| Q4 24 | -6.4% | 41.6% | ||
| Q3 24 | -31.0% | 32.5% | ||
| Q2 24 | 3.5% | -98.1% | ||
| Q1 24 | 52.5% | 26.1% |
| Q4 25 | — | 28.4% | ||
| Q3 25 | -35.9% | 28.1% | ||
| Q2 25 | -15.4% | 28.1% | ||
| Q1 25 | -62.2% | 27.6% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | -57.2% | 26.7% | ||
| Q2 24 | -83.9% | 52.4% | ||
| Q1 24 | 44.3% | 24.1% |
| Q4 25 | $0.32 | $0.96 | ||
| Q3 25 | $-0.16 | $0.94 | ||
| Q2 25 | $-0.06 | $0.92 | ||
| Q1 25 | $-0.21 | $0.88 | ||
| Q4 24 | $-0.14 | $0.91 | ||
| Q3 24 | $-0.15 | $0.84 | ||
| Q2 24 | $-0.33 | $1.20 | ||
| Q1 24 | $0.34 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $2.1B |
| Total Assets | $465.9M | $18.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | $-302.0M | $2.1B | ||
| Q3 25 | $-451.4M | $2.1B | ||
| Q2 25 | $-433.5M | $2.1B | ||
| Q1 25 | $-426.2M | $2.0B | ||
| Q4 24 | $-388.7M | $2.0B | ||
| Q3 24 | $-370.2M | $2.0B | ||
| Q2 24 | $-344.2M | $1.9B | ||
| Q1 24 | $-294.3M | $1.7B |
| Q4 25 | $465.9M | $18.9B | ||
| Q3 25 | $364.0M | $18.8B | ||
| Q2 25 | $347.1M | $18.6B | ||
| Q1 25 | $324.0M | $18.3B | ||
| Q4 24 | $343.8M | $18.2B | ||
| Q3 24 | $314.1M | $18.5B | ||
| Q2 24 | $352.3M | $18.5B | ||
| Q1 24 | $373.1M | $18.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $243.9M |
| Free Cash FlowOCF − Capex | — | $232.0M |
| FCF MarginFCF / Revenue | — | 113.6% |
| Capex IntensityCapex / Revenue | 0.0% | 5.9% |
| Cash ConversionOCF / Net Profit | — | 4.21× |
| TTM Free Cash FlowTrailing 4 quarters | — | $409.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $243.9M | ||
| Q3 25 | $-4.3M | $66.2M | ||
| Q2 25 | $-31.4M | $37.6M | ||
| Q1 25 | $-22.6M | $82.4M | ||
| Q4 24 | $-35.0M | $116.9M | ||
| Q3 24 | $-35.3M | $59.5M | ||
| Q2 24 | $-7.2M | $16.7M | ||
| Q1 24 | $53.8M | $-58.5M |
| Q4 25 | — | $232.0M | ||
| Q3 25 | — | $62.7M | ||
| Q2 25 | — | $34.5M | ||
| Q1 25 | — | $80.6M | ||
| Q4 24 | — | $93.4M | ||
| Q3 24 | $-35.5M | $51.2M | ||
| Q2 24 | $-7.3M | $10.5M | ||
| Q1 24 | $53.8M | $-63.6M |
| Q4 25 | — | 113.6% | ||
| Q3 25 | — | 31.0% | ||
| Q2 25 | — | 17.4% | ||
| Q1 25 | — | 41.4% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | -68.7% | 26.7% | ||
| Q2 24 | -9.9% | 7.4% | ||
| Q1 24 | 39.0% | -36.9% |
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 15.1% | ||
| Q3 24 | 0.3% | 4.3% | ||
| Q2 24 | 0.1% | 4.4% | ||
| Q1 24 | 0.1% | 2.9% |
| Q4 25 | — | 4.21× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 0.67× | ||
| Q1 25 | — | 1.54× | ||
| Q4 24 | — | 2.08× | ||
| Q3 24 | — | 1.16× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | 0.88× | -1.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TRMK
Segment breakdown not available.
